Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: Alpelisib
Drug: Cisplatin

First Posted Date: 2015-12-03

Last Posted Date: 2020-01-10

Lead Sponsor: Pamela Munster

Target Recruit Count: 28

Registration Number: NCT02620839

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Phase 3

Conditions: Esophageal Squamous Cell Carcinomas

Interventions: Drug: Nimotuzumab
Drug: Paclitaxel
Drug: Placebo
Drug: Cisplatin

First Posted Date: 2015-11-23

Last Posted Date: 2016-02-01

Lead Sponsor: Biotech Pharmaceutical Co., Ltd.

Target Recruit Count: 504

Registration Number: NCT02611700

Locations: 🇨🇳
Chinese PLA General Hospital Medical School of Chinese PLA, Beijing, Beijing, China
🇨🇳
Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳
AnHui Provincial Hospital, Hefei, Anhui, China

and more 24 locations

Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma

Phase 3

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Radiation: Intensity-modulated radiotherapy
Drug: Cisplatin

First Posted Date: 2015-11-20

Last Posted Date: 2015-11-20

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 462

Registration Number: NCT02610010

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2015-11-20

Last Posted Date: 2022-03-23

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 21

Registration Number: NCT02608684

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Phase 2

Active, not recruiting

Conditions: Malignant Pleural Mesothelioma
Mesothelioma

Interventions: Drug: Cisplatin
Drug: Methotrexate
Drug: Gemcitabine
Other: Lung Cancer Symptom Scale for Mesothelioma Questionnaire

First Posted Date: 2015-11-20

Last Posted Date: 2024-11-28

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 34

Registration Number: NCT02611037

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

Phase 2

Completed

Conditions: Nasopharyngeal Cancer

Interventions: Drug: Capecitabine
Drug: Cisplatin

First Posted Date: 2015-11-18

Last Posted Date: 2016-03-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 45

Registration Number: NCT02608073

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2

Withdrawn

Conditions: Stage IIIA Non-Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Procedure: Computed Tomography
Drug: Docetaxel
Radiation: Fludeoxyglucose F-18
Drug: Gemcitabine Hydrochloride
Drug: Pemetrexed Disodium
Procedure: Positron Emission Tomography

First Posted Date: 2015-11-18

Last Posted Date: 2023-05-25

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Registration Number: NCT02607423

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer(NSCLC)

Interventions: Drug: JinFuKang
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2015-11-11

Last Posted Date: 2019-09-20

Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Target Recruit Count: 218

Registration Number: NCT02603003

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Carcinoma
Metastatic Malignant Neoplasm in the Brain
Metastatic BRCA Hereditary Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Drug: Veliparib

First Posted Date: 2015-11-04

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 333

Registration Number: NCT02595905

Locations: 🇺🇸
Newark Radiation Oncology, Newark, Ohio, United States
🇺🇸
Saint Charles Hospital, Oregon, Ohio, United States
🇺🇸
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States

and more 807 locations

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Phase 1

Active, not recruiting

Conditions: Stage II Vaginal Cancer AJCC v6 and v7
Stage IVA Vaginal Cancer AJCC v6 and v7
Advanced Vaginal Adenocarcinoma
Advanced Vaginal Adenosquamous Carcinoma
Advanced Vaginal Squamous Cell Carcinoma
Stage IVA Cervical Cancer AJCC v6 and v7
Stage IIIB Cervical Cancer AJCC v6 and v7
Advanced Cervical Adenocarcinoma
Advanced Cervical Adenosquamous Carcinoma
Advanced Cervical Squamous Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Radiation: Brachytherapy
Drug: Cisplatin
Procedure: Computed Tomography
Radiation: External Beam Radiation Therapy
Other: Fludeoxyglucose F-18
Radiation: High-Dose Rate Brachytherapy
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Other: Pharmacological Study
Procedure: Positron Emission Tomography
Drug: Triapine

First Posted Date: 2015-11-04

Last Posted Date: 2024-11-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT02595879

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 14 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy